Investor Presentation H1 2023

148 Investor presentation First six months of 2023 Rare disease segment has lower profitability driven by higher investments in R&D including the acquisition of Forma in 2022 Diabetes and Obesity care P&L - full year 2022 DKK billion 200 -15% 160 -27% 120 80 40 Sales ratios Rare disease P&L - full year 2022 DKK billion 25 25 -25% 20 20 15 -13% -3% 1% 43% 10 5 -19% Novo NordiskⓇ Sales ratios -19% -2% +1% 36% 0 0 Sales COGS S&D R&D Admin ΟΟΙ OP Sales COGS S&D R&D Admin ΟΟΙ OP P&L: Profit and Loss; COGS: Cost of goods sold; OOI: Other operating income; OP: Operating profit; S&D: Sales and distribution costs; R&D: Research and development costs; Admin: Administrative costs

View entire presentation